Arbutus Biopharma (ABUS) Interest Coverage Ratio (2017 - 2026)
Arbutus Biopharma (ABUS) posted Interest Coverage Ratio of 7343.83 for Q1 2026, up 2598.84% sequentially from 293.89 in Q4 2025, and up 900.14% YoY from 734.28 in Q1 2025.
Powered by 
Analysis
Arbutus Biopharma (ABUS) Interest Coverage Ratio (2017 - 2026) Analysis & Trends
Arbutus Biopharma has reported Interest Coverage Ratio for 14 years, with the latest figure at 7343.83 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 900.14% year-over-year to 7343.83 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6802.04 (up 6263.85% YoY) and the FY2025 annual result came in at 0.21, up 51.64% from the prior year.
- Interest Coverage Ratio advanced to 7343.83 in Q1 2026 per ABUS's latest filing, from 293.89 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 7343.83 in Q1 2026 and troughed at 917.82 in Q1 2025.
- A 5-year average of 221.26 and a median of 107.51 in 2023 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2023 and 2026: Interest Coverage Ratio sank 1028.81% in 2023, then surged 900.14% in 2026.
- Over 5 years, Interest Coverage Ratio stood at 73.02 in 2022, then tumbled by 55.27% to 113.37 in 2023, then soared by 75.86% to 27.37 in 2024, then sank by 973.63% to 293.89 in 2025, then surged by 2598.84% to 7343.83 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 7343.83, 293.89, and 376.48 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | -21.24 |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 1.42 |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 10 | Arbutus Biopharma | 1.01 Bn | 921.39 Mn | - | -331.33 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -331.33 |
| Mar 31, 2026 | 9,935.76 |
| Dec 31, 2025 | -293.89 |
| Sep 30, 2025 | -376.48 |
| Jun 30, 2025 | 53.14 |
| Mar 31, 2025 | -917.82 |
| Dec 31, 2024 | -464.43 |
| Sep 30, 2024 | -739.31 |
| Jun 30, 2024 | -634.79 |
| Mar 31, 2024 | -440.07 |
| Dec 31, 2023 | -471.52 |
| Sep 30, 2023 | -468.65 |
| Jun 30, 2023 | -107.51 |
| Mar 31, 2023 | -87.94 |
| Dec 31, 2022 | -73.02 |
| Sep 30, 2022 | -41.52 |
| Jun 30, 2022 | -29.27 |
| Mar 31, 2022 | -21.69 |
| Dec 31, 2021 | -37.14 |
| Sep 30, 2021 | -24.16 |